Source Newsroom: Pressure Point Inc.
Newswise — Tinton Falls, NJ – February 6, 2013 – Pressure Point Inc., a global medical device company is proud to announce that Health Canada has granted the company an establishment license for its Pressure Right® low-risk, Class 1 (Rx) antiemetic medical device for anesthesia use in hospitals.
Effective immediately, as part of Pressure Point’s continued roll-out campaign into international markets, the company intends to introduce their antiemetic medical device to Canadian hospitals for patients having a history of postoperative nausea and vomiting (PONV).
In the US, Pressure Right® is used in concert with antiemetic drug therapy by anesthesiologists to improve patient satisfaction with the management of PONV following surgery. In April 2011, Pressure Point achieved 510(k) premarket notification clearance from the US Food and Drug Administration for its Pressure Right® disposable P6 stimulation wrist strip.
The patent-pending Pressure Right® wrist strip is designed to be applied to patients’ wrists generally before the induction of anesthesia. It provides stimulation to the patient’s P6 acupressure point located on the forearm-wrist area to achieve a prolonged antiemetic effect.
Joseph DiLustro, Chairman and CEO of Pressure Point, is extremely pleased to add Canada to its list of international markets.
In the fall of 2012, Pressure Point announced an agreement with an established distributor network to sell into the Chinese market in 2014. The company is currently going through the product approval phase with the SFDA in China. In just a short time, Pressure Point has implemented a strategic plan to have Pressure Right® represented not only in the US, but also in international markets.
DiLustro said, “Our market focus is to broaden the globalization reach of Pressure Right® everywhere in the world.”